Recent news highlights Phibro's upcoming Q4 earnings and ongoing business momentum in animal health, reflecting active market engagement and operational developments.

• Phibro's Q4 earnings preview discusses factors beyond headline estimates, emphasizing animal health momentum aiding results [N1].
• The company completed a major acquisition of Zoetis's medicated feed additive portfolio, expanding product lines and manufacturing capabilities [S1].
• Phibro maintains a strong liquidity position with a current ratio of 2.96 and net income of $99.7 million for fiscal year 2026 [S1].
• Geopolitical tensions in the Middle East, especially in Israel where Phibro has significant operations, pose potential risks to supply chain and manufacturing continuity [S1].
• Phibro has implemented comprehensive cybersecurity measures including managed detection and response services and regular risk assessments to mitigate IT risks [S1].

Phibro's acquisition of Zoetis's medicated feed additive portfolio expanded its product offerings and geographic reach, strengthening its market position in animal health. The company's broad global manufacturing and research footprint supports operational flexibility and supply chain management. Its liquidity position, with a current ratio near 3.0 and positive net income, indicates financial stability. The company’s focus on cybersecurity and risk mitigation enhances operational resilience. Demand for animal health products driven by global protein consumption trends supports ongoing business activity. Recent news coverage indicates active market interest and business momentum in the animal health segment [N1].

Phibro faces geopolitical risks due to ongoing conflicts in the Middle East, particularly in Israel where it has significant manufacturing operations and employees, which could disrupt production and supply chains. Legal claims and litigation typical in the industry may result in material adverse effects if unfavorable outcomes occur. The company's exposure to currency fluctuations, regulatory changes, and supply chain disruptions could impact operations. While liquidity is strong, reliance on credit facilities and debt from acquisitions introduces financial risk. Cybersecurity threats remain a persistent risk despite mitigation efforts. Market competition and regulatory pressures in the animal health industry may constrain growth and profitability.

Phibro's moat is supported by its diversified global product portfolio in animal health and mineral nutrition, serving a broad customer base across multiple continents. The acquisition of Zoetis's medicated feed additive portfolio added scale, product breadth, and manufacturing capabilities, enhancing competitive positioning. The company's extensive manufacturing footprint, including specialized facilities in multiple countries, supports supply chain resilience and product availability. Its established relationships with thousands of customers and presence in approximately 90 countries contribute to market penetration and brand recognition. Additionally, ongoing investments in cybersecurity and risk management help protect operational continuity. However, exposure to geopolitical risks, particularly in Israel, and industry regulatory challenges remain factors influencing the moat's strength.

• Geopolitical Risks: Ongoing conflicts in the Middle East, especially in Israel where Phibro has manufacturing sites and employees, may disrupt operations, supply chains, and logistics, impacting business continuity.
• Legal and Regulatory Risks: The company faces claims and litigation related to competition law, labor, consumer protection, product liability, intellectual property, and other areas, which could have material adverse effects if resolved unfavorably.
• Cybersecurity Risks: Phibro is exposed to information technology system failures, network disruptions, and cyber threats. Despite active mitigation programs, evolving threats pose ongoing risks to operations and data security.
• Financial Risks: The company has debt related to acquisitions and credit agreements. Changes in interest rates, currency fluctuations, and credit availability could affect financial condition and flexibility.
• Market and Industry Risks: Phibro operates in a competitive and regulated animal health industry. Changes in demand, regulatory environment, and supply chain disruptions could impact sales and profitability.

• Phibro Animal Health Corporation is a global diversified animal health and mineral nutrition company developing, manufacturing, and marketing products for food animals including poultry, beef and dairy cattle, swine, aquaculture, and dogs.
• The company markets approximately 790 product lines in about 90 countries to roughly 4,800 customers.
• In October 2024, Phibro completed the acquisition of Zoetis Inc.'s medicated feed additive portfolio and related assets for approximately $297.5 million, which included six manufacturing sites in the U.S., Italy, and China.
• The acquired portfolio generated $407.6 million in revenue in 2023 and contributed $358.2 million and $208.2 million to net sales in fiscal years 2026 and 2025, respectively.
• Phibro operates multiple manufacturing and research facilities globally, including significant sites in Israel, Brazil, the U.S., China, and Europe, with Israeli operations accounting for 18% of consolidated assets and 16% of net sales as of June 30, 2026.
• The company has a 2024 Credit Agreement amended in April 2026 to increase revolving credit commitments to $435 million, providing enhanced operating flexibility.
• As of June 30, 2026, Phibro reported cash and equivalents of $61.4 million, short-term investments of $20.6 million, current assets of $935.5 million, and current liabilities of $316.5 million, resulting in a current ratio of 2.96 and a cash ratio of 0.26.
• Net income for the fiscal year ended June 30, 2026, was $99.7 million, with basic and diluted EPS of $2.46 and $2.43, respectively.
• Phibro faces geopolitical risks due to ongoing conflicts in the Middle East, particularly in Israel where it has manufacturing sites and approximately 525 employees, which could disrupt operations and supply chains.
• The company maintains cybersecurity programs including managed detection and response services, regular penetration testing, and training to mitigate information technology risks.
• Phibro is subject to various legal claims and litigation typical for its industry and jurisdictions, which could have material adverse effects if unfavorable outcomes occur.
• The company intends to pay regular quarterly dividends subject to board approval and financial condition.
• Recent news coverage includes previews of Q4 earnings and discussions of animal health momentum supporting results, indicating ongoing business activity and market interest.